Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Change in Accured Expenses (2016 - 2025)

Avanos Medical's Change in Accured Expenses history spans 11 years, with the latest figure at -$7.7 million for Q4 2024.

  • For Q4 2024, Change in Accured Expenses rose 3.75% year-over-year to -$7.7 million; the TTM value through Dec 2024 reached -$11.4 million, up 58.84%, while the annual FY2025 figure was -$12.9 million, 13.16% down from the prior year.
  • Change in Accured Expenses for Q4 2024 was -$7.7 million at Avanos Medical, down from $7.0 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $59.8 million in Q3 2020 and bottomed at -$104.7 million in Q4 2020.
  • The 5-year median for Change in Accured Expenses is -$5.6 million (2021), against an average of -$4.4 million.
  • The largest annual shift saw Change in Accured Expenses plummeted 3300.0% in 2023 before it skyrocketed 276.04% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$104.7 million in 2020, then surged by 155.3% to $57.9 million in 2021, then tumbled by 80.31% to $11.4 million in 2022, then tumbled by 170.18% to -$8.0 million in 2023, then grew by 3.75% to -$7.7 million in 2024.
  • Per Business Quant, the three most recent readings for AVNS's Change in Accured Expenses are -$7.7 million (Q4 2024), $7.0 million (Q3 2024), and $16.9 million (Q2 2024).